MAY 29-30, 2013
MARRIOTT MARQUIS HOTEL | NYC
|
Postdocs & Grad Students: Want to attend the Meeting for free? Present a poster in Innovation Alley (sponsored by Merck)! Click here for details
Small and mid-size companies: See and be seen! Present your company in the NYBA Annual Meeting Corporate Showcase and receive complimentary 1-day conference registration . Details here. |
 | |
President & CEO
Hoffman-LaRoche
2001-2009
Chairman
Brickell Biotech
Vice-Chairman
Project Hope
Chairman-Elect
Biocryst Pharma
Board Member
Tranzyme Pharma
Board Member
Glaxo Wellcome Foundation
|
Invitation-only
CEO Leadership Breakfast
Sponsored by
Thursday, May 30, 7:00 AM
Keynote Address
George B. Abercrombie, RPh, MBA
former President and Chief Executive Officer
Hoffmann-La Roche Inc.
This exclusive breakfast event brings together the industry leadership for a morning of information, insight, and networking. Breakfast is headlined by George Aberercrombie, former President and CEO of Hoffman-LaRoche and a driving force behind Roche's development over the past decade.
Attendance for the CEO Leadership Breakfast is restricted to top level Annual Meeting sponsors and C-level executives by invitation only.
To request an invitation (C-level leadership of a bioscience research, discovery or commercialization company only), click here.
|
|
BIOSCIENCE MEANS BUSINESS:
Business and Finance at the NYBA 22nd Annual Meeting
|
WEDNESDAY MAY 29, 10:45 AM
Emerging Legal Risks in Clinical Trials
Exciting developments in clinical research have brought new legal challenges. Evolving research risk stems from several sources: the advancement of technology, an increased awareness of research subjects' legal rights, and the involvement of patient advocacy groups and related third-party organizations. Learn how to recognize new legal challenges and mitigate the risks they pose in clinical trials. This fast-paced session will address legal issues related to hot topics such as genomics, personalized medicine, biobanking and genetic privacy. This panel will discuss indemnification, subject injury, informed consent, HIPAA authorizations and data protection/access.
Karen Dietz
Counsel
Multiple Myeloma Research Foundation
Paul S. Appelbaum, MD
Dollard Professor of Psychiatry, Medicine, & Law Director, Division of Law, Ethics & Psychiatry Department of Psychiatry Columbia University College of Physicians & Surgeons
Justin P. McCarthy, Esq.
Senior Vice President & Associate General Counsel Chief Counsel R&D Pfizer
Linda Malek
Partner
Moses & Singer
|
WEDNESDAY MAY 29, 3:30 PM
Pharma-Biotech Dealmaking
Pharmaceutical and biotech companies are turning with increasing frequency to in-licensing and collaboration agreements - pharmaceutical companies to put new products in their pipelines and biotech companies to access the resources needed for final-stage development, clinical trials, manufacturing, and distribution.
Rebecca Ashkenazy, MD Strategy Lead Pfizer Inc.
Christine de los Reyes, PharmD, MBA Vice President, Strategic Planning & Business Development Alopexx Enterprises, LLC
Cyndi Green, PhD, MBA Director, Worldwide Business Development Pfizer Inc.
Ted Miller, PhD Head, U.S. Business Development Midatech
|
WEDNESDAY MAY 29, 3:30 PM
Starting a Biotech Company: Issues to Consider
Starting a new company is no routine endeavor. For even the most serial of entrepreneurs, there are many decisions (both business and legal) which need to be made and factors to be considered when creating a successful and sustaining enterprise. Where are the pitfalls and where are the opportunities? The panelists at this session will provide practical advice on how to best deal with the start-up process, as well as impart information on tax employment compensation benefits, estate planning benefits, and potential grants available to new companies. |
WEDNESDAY, MAY 29, 3:30 PM
Venture Capital Available to New York Companies
There is increasing attention to the deficit in VC investing in NY life science companies relative to factors such as the caliber and quantity of academic research in the state (NY is #3 in NIH funding). While this situation is not new, the success of NY biotech companies such as Regeneron and Acorda, the efforts of Gov. Cuomo's Regional Economic Development Councils to grow the life science industry in the state, and efforts to create new VC pools dedicated to investments in the state give new timeliness to this topic. One suggested panelist is the head of the in-state investment program of the NY State Comptroller. This program has been expanded in the last few years, yet is not widely known, and may not be focused enough on the needs of early-stage companies to have maximum impact.
|
THURSDAY, MAY 30, 9:00 AM
Filling Pipelines & Getting New Products to Market: Innovative Paradigms of Discovery & Development
Drug discovery and drug development paradigms are changing. Drug development is becoming increasingly more challenging and is no longer leading to an influx of innovative new therapies to the market. The President's Council of Advisor's on Science and Technology (PCAST) recently set a goal that the United States double the number of innovative medicines approved in the next 10 to 15 years. Private-public partnerships between industry, academia, patient groups, and foundations are increasing with the goal of improving the discovery and development of new drugs. Companies are exploring virtual models to decrease the cost of drug development. Recent changes in the law are aimed at optimizing and accelerating the FDA review process for new drugs. Panelists with government, industry, and investment experience will share their insights and experiences with innovative models of drug discovery and development.
Afia K. Asamoah Senior Associate Covington & Burling LLP
Dr. Joan Fallon CEO Curemark
Jonathan S. Leff Partner, Deerfield Chairman, Deerfield Institute
|
THURSDAY, MAY 30, 9:00 AM
Public Markets: Friend of Foe?
2013 has seen a sharp rise in the number of biotech IPO's and public company listings. The panel will review the current state of the public marketplace, thoughts on the sustainability of this market , and define what is needed to complete a successful IPO today. The panel will also discuss the implications of recent legislation on IPOs, including the JOBS Act that includes provisions to make it easier for companies to go public; review public market investor sentiment and highlight alternative IPO pathways.
|
THURSDAY, MAY 30, 11:45 AM
Building Bioscience in New York
In 1999 the Center for an Urban Future published a report entitled "Biotechnology: The Industry That Got Away." Since that time, a variety of initiatives have been launched with the focus of building New York into a biotech center. What, if anything, has changed since 1999? Why have Pfizer and Roche established research centers in NYC? What is the prognosis for the life sciences in the Empire State?
Eva Brown Cramer, PhD Vice President for Biotechnology and Scientific Affairs SUNY Downstate Medical Center
Kenneth Adams CEO and President Empire State Development Corp NYS Commissioner for Economic Development
Lenzie Harcum Bioscience Lead New York City Economic Development Corp
Judith Dunn Head Translational Clinical Research Center Roche Jonathan Bowles Executive Director The Center for an Urban Future
Fritz Bittenbender Vice President, Alliance Development and State Government Affairs BIO
|
WED, MAY 29, 12:00 PM
Keynote Luncheon
Sponsored by
John Herrmann, PhD
Chief Science Officer
Global External R&D
Dr. Herrmann leads an Eli Lilly team responsible for global sourcing and initial risk assessments of innovations in oncology that fit Lilly oncology strategy & portfolio needs and/or could be swiftly assessed in rapid proof-of-concept models.
He received his Ph.D. from The University of Texas M.D. Anderson Cancer Center with a research focus on mechanisms of tumor metastasis and ways to overcome mutli-drug resistance conferred by members of the Bcl-2 family. This work lead to focus on the Ubiquitin-proteasome pathway as a new intervention point and ultimately to a collaboration with Proscript/Leukocyte/Millennium. Dr. Herrmann subsequently joined CuraGen as chief of a cancer discovery team applying genome-wide methods of gene expression, protein-protein interactions and functional assays to support such alliances as Abgenix to generate full human Mabs against qualified targets. He then joined CEPTYR, Inc., where as head of discovery. He switched career tracks and joined Serono (pre Merck KGaA and after the acquisition creating Merck Serono) to lead a new team to source & risk assess external innovations in oncology attuned to portfolio management needs and balance.
THURSDAY, MAY 30, 1:00 PM
Margaret Anderson
Executive Director
Margaret Anderson is executive director of FasterCures/The Center for Accelerating Medical Solutions, defining the organization's strategic priorities and positions on key issues, developing its programmatic portfolio, and managing its operations. Prior to her appointment as executive director, she was FasterCures' chief operating officer for five years. She has extensive experience in managing biomedical and public health initiatives and facilitating multi-sector collaborations.
She is a founding board member and past-president of the Alliance for a Stronger FDA, co-chairs the eHealth Initiative's Council on Data and Research, is on the board of the National Health Council, and is a member of the National Center for Advancing Translational Sciences Advisory Council, the Cures Acceleration Network Review Board, the National Health Council Board of Directors, United for Medical Research Steering Committee, and the Institute of Medicine's Forum on Drug Discovery, Development and Translation. She served as a board member of the Council for American Medical Innovation and the Coalition for the Advancement of Medical Research.
Anderson joined FasterCures after five years at the Academy for Educational Development (AED) in Washington. At AED, she was the deputy director and a team leader in the Center on AIDS & Community Health. Her responsibilities included financial and budget oversight; management of a team, projects, and staff; and strategic planning. She managed a portfolio that consisted of grants and contracts from the Centers for Disease Control and Prevention, the Ford Foundation, and the Annie E. Casey Foundation.
|
|
|
Thank you to the sponsors of the NYBA 22nd Annual Meeting
|
Broad Hollow Bioscience Park BusinessWire Chubb Group of Insurance Companies Consolidated Edison Healthcare Businesswomen's Association Keck Graduate Institute KPMG Metanomics Health - a BASF Company Nature Publishing Group Paul Hastings LLP SUNY Downstate Medical Center SUNY Research Foundation Target Health Inc. Versilant Technologies
|
|
|
|
|